• Gilead Sciences' (GILD.US) new experimental drug show signs of being effective in treating coronavirus
• President Trump plans to reopen American economy
• Stocks traded in green on hopes for coronavirus treatment
European indices finished today's session higher as investors hope that an experimental drug developed by Gilead Sciences could help treat Covid-19. The markets have also responded positively to the news that some countries will start loosening the restrictions imposed to combat the rapid spread of the coronavirus despite the fact that the number of infections is still increasing. Dax finished today’s session 3.2% higher, CAC40 rose 3.4% , FTSE 100 gained 2.8 %, IBEX35 advanced 1.7%.
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appU.S. stock markets opened sharply higher only to erase some of their gains, as President Trump unveiled plans to reopen the US economy. States that have seen a consistent decline in the number of coronavirus infections can allow public interactions in a month. US indexes were also supported by an 7.7% rise in Gilead Sciences (GILD.US) stock and by news that Boeing (BA.US) is planning to partially resume production at its Washington state plant from Monday. The dollar index dropped slightly to around 99.8 after two days of gains. Dow Jones advanced 1.98%, S&P rose 1.8% and NASDAQ gained 0.73%.
Hopes that a coronavirus treatment is near completely overshadowed the recent disastrous US economic data and more importantly, today's GDP data for the first quarter from China which fell by 6.8% y / y and almost 10% compared to the last quarter of last year. In addition, retail sales fell by more than 15% in March. This is a smaller number compared to February, however analysts expected a decline of just 10%. More importantly, China reported worrying death statistics from the Wuhan region, adding more than 1,000 cases today. Despite this, sentiment in Asian markets remained very positive.
There are no major data prints scheduled for release on Monday besides China’s deposit and loan rate . On the earnings front IBM, M&T Bank Corp., Zions Bancorporation and Philips N.V will publish their quarterly results. Next week, investors will try to asses whether the virus is at its peak or has reached its peak in some countries and regions. Needless to say, financial markets will pay attention to further updates regarding coronavirus outbreak.
USDCAD – yesterday bulls failed to test the 1.4289 resistance level. Today price made a small pullback and is heading towards major support at 1.3909. This level is also being strengthened by previous price reactions and crosses with the downward trend line. As long as the price sits above this confluence zone, upward move may occur. However if the bears take control of the market then support at 1.3709 may come into play. Source:xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
